Stockreport

Benitec Biopharma's BB-301: Potential In OPMD But Still Too Early Stages [Seeking Alpha]

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF Play 12min Summary Benitec Biopharma develops genetic therapies using its proprietary ddRNAi platform. BB-301, which targets OPMD, has shown promising interim tri [Read more]